FDA issued Emergency Use Authorization for potential COVID-19 treatment
On May 1, 2020, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug remdesivir…
-
-
USC study showed Alzheimer’s gene triggers early breakdowns in the blood-brain barrier, predicting cognitive decline
On May 1, 2020, a University of Southern California (USC) study suggested that temporarily suppressing the body’s immune…
-
CDC launched the National Healthcare Safety Network COVID-19 Module Data Dashboard
On May 1, 2020, the CDC launched the National Healthcare Safety Network (NHSN) COVID-19 Module Data Dashboard showing…
-
US Dept of Veterans Affairs participated in drug, plasma trials in fight against COVID-19
On May 1, 2020, the U.S. Dept. of Veterans Affairs (VA) announced participation in a series of clinical…
-
CDC launched national viral genomics consortium to better map SARS-CoV-2 transmission
On May 1, 2020, the CDC launched the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance…
-
CHF Solutions shipped Aquadex product to COVID-19 specialty center in Minnesota
On May 1, 2020, CHF Solutions announced that it has shipped Aquadex product to a specialty care center…
-
Cancer patients face high mortality from COVID-19
On May 1, 2020, people with cancer who develop COVID-19 are much more likely to die from the…
-
Athersys and University Hospitals Cleveland Medical Center announce activation of first clinical site for MACOVIA study for COVID-19 Induced ARDS
On May 1, 2020, Athersys and University Hospitals Cleveland Medical Center (UH Cleveland) announced that UH Cleveland is…
-
XBiotech identified ‘super bloods’ for development of True Human COVID-19 therapy
On May 1, 2020, XBiotech announced that human immune donors had been identified that can support the Company’s…
-
COVID-19 | FDA | Therapeutics
Gilead announced investigational antiviral remdesivir received FDA Emergency Use Authorization for treatment of COVID-19
On May 1, 2020, Gilead announced the FDA granted emergency use authorization (EUA) for the investigational antiviral remdesivir…
-
FDA included ventilator developed by NASA in ventilator Emergency Use Authorization
On Apr. 30, 2020, the FDA included, under the ventilator emergency use authorization (EUA), a ventilator developed by…
-
Mesoblast began enrollment in phase 2/3 clinical trial of remestemcel-L in 300 patients with acute respiratory distress syndrome
On Apr. 30, 2020, Mesoblast announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic…
-
AstraZeneca and Oxford University announced landmark agreement for COVID-19 vaccine
On Apr. 30, 2020, AstraZeneca and the University of Oxford announced an agreement for the global development and…
-
Oxford University announced a landmark partnership for development of COVID-19 vaccine
On Apr. 30, 2020, University of Oxford announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for…
-
Fujifilm Diosynth teamed with COVID-19 Therapeutics Accelerator to reserve manufacturing capacity for COVID-19 therapies
On Apr. 30, 2020, FUJIFILM announced that it will reserve manufacturing capacity for a future COVID-19 therapy for…
-
Landmark partnership announced for development of COVID-19 vaccine
On Apr. 30, 2020, the University of Oxford announced an agreement with the UK-based global biopharmaceutical company AstraZeneca…
-
City of Hope began CIRM-funded Coronavirus study
On Apr. 30, 2020, The California Institute for Regenerative Medicine (CIRM) awarded $750,000 to City of Hopeﾒs John…
-
Vaxart announced additional positive pre-clinical data for oral COVID-19 vaccine program
On Apr. 30, 2020, Vaxart announced it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with…
-
Mateon announced peer reviewed publication on its R&D effort against COVID-19
On Apr. 30, 2020, Mateon Therapeutics reported several peer-reviewed publications derived from its R&D effort against COVID-19. Published…
-
Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda
On Apr. 30, 2020, Eiger BioPharmaceuticals announced that the first patients have been dosed in a Phase 2…
-
Nature publication presents new ‘Blueprint’ revealed how SARS-CoV-2 virus hijacks human cells
On Apr. 30, 2020, an international team of more than 120 scientists has detailed the impact of 75…
-
Emory University launched study on COVID-19 immune responses
On Apr. 30, 2020, Emory University researchers are taking part in a multi-site study across the U.S. to…
-
INOVIO expanded manufacturing of COVID-19 DNA vaccine INO-4800 with new funding from CEPI
On Apr. 30, 2020, INOVIO announced an agreement to expand its manufacturing partnership with the German contract manufacturer…
-
The US Dept. of Veterans Affairs joined XPRIZE Pandemic Alliance to combat COVID-19 and future outbreaks
On Apr. 29, 2020, the U.S. Dep. of Veterans Affairs (VA) announced a partnership with the XPRIZE Foundationﾒs…
-
NIH mobilized national innovation RADx initiative for COVID-19 diagnostics
On Apr. 29, 2020, the NIH announced a new initiative aimed at speeding innovation, development and commercialization of…
-
Gilead announced results from phase 3 trial of investigational antiviral Remdesivir in patients with severe COVID-19
On Apr. 29, 2020, Gilead announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and…
-
Clinical trial in COVID-19 patients tests anti-inflammatory drug developed 25 years ago at Scripps Research
On Apr. 29, 2020, an anti-inflammatory drug developed at Scripps Research 25 years ago tested as a way…
-
Emory University helped lead research on drug to treat COVID-19 patients
On Apr. 29, 2020, Emory University played a leading role in the government-sponsored clinical trial of the COVID-19…
-
University of Nebraska Medical Center remdesivir clinical trial show accelerated recovery from advanced COVID-19
On Apr. 29, 2020, hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than…
-
Catalent signs agreement with Johnson & Johnson to be US manufacturing partner for lead COVID-19 vaccine candidate
On Apr. 29, 2020, Catalent announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby…
